Have a feature idea you'd love to see implemented?
Let us know!
PLRX Pliant Therapeutics Inc
Price (delayed)
$13.68
Market cap
$831.76M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.09
Enterprise value
$810.12M
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual
Highlights
PLRX's gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Key stats
What are the main financial stats of PLRX
Market
Valuations
Earnings
Shares outstanding
60.8M
Market cap
$831.76M
Enterprise value
$810.12M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.1
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$183.45M
EBITDA
-$178.42M
Free cash flow
-$139.79M
Per share
Balance sheet
Liquidity
EPS
-$3.09
Free cash flow per share
-$2.32
Book value per share
$6.51
Revenue per share
$0
TBVPS
$8.01
Total assets
$483.73M
Total liabilities
$91.05M
Debt
$60.23M
Equity
$392.68M
Working capital
$416.63M
Debt to equity
0.15
Current ratio
14.47
Quick ratio
14.17
Net debt/EBITDA
0.12
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-36%
Return on equity
-41%
Return on invested capital
-41.7%
Return on capital employed
-40.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PLRX stock price
How has the Pliant Therapeutics stock price performed over time
Intraday
-3.73%
1 week
-6.75%
1 month
20.74%
1 year
0.22%
YTD
-24.46%
QTD
22.03%
Financial performance
How have Pliant Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$207.75M
Net income
-$185.41M
Gross margin
N/A
Net margin
N/A
PLRX's gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year
PLRX's operating income is down by 31% year-on-year and by 7% since the previous quarter
The net income has contracted by 28% YoY and by 9% from the previous quarter
Growth
What is Pliant Therapeutics's growth rate over time
Valuation
What is Pliant Therapeutics stock price valuation
P/E
N/A
P/B
2.1
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 13% year-on-year and by 8% since the previous quarter
The equity has contracted by 26% YoY and by 10% from the previous quarter
PLRX's price to book (P/B) is 22% lower than its 5-year quarterly average of 2.7 but 5% higher than its last 4 quarters average of 2.0
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Efficiency
How efficient is Pliant Therapeutics business performance
The ROE has declined by 24% year-on-year and by 17% since the previous quarter
The company's return on invested capital fell by 18% YoY and by 13% QoQ
Pliant Therapeutics's return on assets has decreased by 18% YoY and by 13% QoQ
Dividends
What is PLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PLRX.
Financial health
How did Pliant Therapeutics financials performed over time
The total liabilities has soared by 118% YoY and by 8% from the previous quarter
The company's quick ratio fell by 25% YoY and by 11% QoQ
Pliant Therapeutics's debt is 85% lower than its equity
The equity has contracted by 26% YoY and by 10% from the previous quarter
PLRX's debt to equity is up by 25% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.